Alloantibodies to red blood cell (RBC) antigens can cause significant hemolytic events. Prior studies have demonstrated that inflammatory stimuli in animal models and inflammatory states in humans, including autoimmunity and viremia, promote alloimmunization. However, molecular mechanisms underlying these findings are poorly understood. Given that Type 1 interferons (IFN-a/b) regulate antiviral immunity and autoimmune pathology, the hypothesis that IFN-a/b regulates RBC alloimmunization was tested in a murine model.
CONCLUSIONS: This study demonstrates that B cells require signaling from IFN-a/b to produce alloantibodies to the human KEL glycoprotein in mice. These findings provide a potential mechanistic basis for inflammationinduced alloimmunization. If these findings extend to human studies, patients with IFN-a/b-associated conditions may have an elevated risk of alloimmunization and benefit from personalized transfusion protocols.
W ith approximately 15 million units of red blood cells (RBCs) transfused per year, RBC transfusion is the most common procedure performed in US hospitals. 1 Unlike ABO and Rh antigens, other common RBC antigens, including Kell, Duffy, and Kidd, are not routinely matched between donor units and recipients. Exposure to allogeneic RBC antigens during transfusion leads to production of antigen-specific alloantibodies in 3% to 10% of transfusion recipients and 30% to 50% of patients with sickle cell disease. 2, 3 Subsequent exposure to the RBC antigen may result in potentially fatal hemolytic transfusion reactions. 4 Additionally, transfusion-dependent patients with hemoglobinopathies, including sickle cell disease, may have rare or multiple RBC alloantibodies. Thus, compatible RBC units for these patients can be exceedingly limited or unattainable, resulting in anemia-associated morbidity and mortality. 5, 6 Elucidating factors that influence alloantibody production could improve prediction of these alloimmune responses and allow for intervention to reduce alloimmunization and hemolytic events. One such factor is the inflammatory state of the transfusion recipient. [7] [8] [9] [10] [11] Ramsey and Smietana 8 reported an increased prevalence of autoimmune disease in alloimmunized patients. More recent studies have reported an increased incidence of alloimmunization in patients with inflammatory bowel disease, febrile transfusion reactions, and sickle cell-mediated acute chest syndrome. 7, 10, 11 Recently, Evers et al. 12 reported that patients with viremia also have an elevated risk of alloimmunization. However, patients with Gram-negative bacteremia had significantly lower rates of alloimmunization. Accordingly, studies in mouse models of alloimmunization have demonstrated that viral mimetics promote RBC alloimmune responses, [13] [14] [15] while lipopolysaccharide inhibits responses. 16 These findings suggest that specific inflammatory pathways associated with certain conditions, including some autoimmune diseases and viral infection, promote RBC alloimmune responses. Recently, Arneja and colleagues 17 demonstrated a role for interleukin (IL)-6 in T-cell responses to stored RBCs. However, other cytokinemediated mechanisms underlying inflammation-induced alloimmunization have not been investigated. The inflammatory conditions that promote alloimmunization are associated with the production of numerous inflammatory cytokines, including tumor necrosis factor-a, IL-12, and IL-6. One class of inflammatory cytokines that regulates both antiviral immunity and autoimmune pathology is the Type I interferon (IFN-a/b) family, consisting of 13 IFN-a genes and one IFN-b gene. In a virally infected cell, recognition of viral nucleic acids by ubiquitously expressed pattern recognition receptors, including Toll-like receptors, results in production and secretion of IFN-a/b. Binding of IFN-a/b to its dimeric receptor, consisting of IFN-a receptor (IFNAR) 1 and IFNAR2, induces expression of IFN-stimulated genes that inhibit viral replication and dissemination. 18 Long-term viral protection is dependent on adaptive immune responses that produce neutralizing antibodies. Studies in murine models of viral infection and immunization have shown that IFN-a/b can enhance or inhibit antibody responses. Multiple studies have reported that injection of IFN-a/b promotes antibody responses to some soluble antigens by increasing activation of dendritic cells (DCs) and lymphocytes. [19] [20] [21] IFNAR signaling has also been implicated in the pathogenesis of multiple autoimmune diseases, including myositis, scleroderma, rheumatoid arthritis, and Sjogren's syndrome. [26] [27] [28] [29] Patients with systemic lupus erythematosus frequently have elevated serum IFN-a/b and IFNstimulated gene expression, which correlate with increased autoantibody levels and disease severity. [30] [31] [32] [33] This association has led to the use of anti-IFN-a/b therapy in clinical trials. 34, 35 The role of IFN-a/b in RBC alloimmunization has not been previously investigated. In comparison to viral and soluble antigens, RBC-bound antigens differ in their route of administration, quantity of antigen, duration of exposure, and accessibility to niches within secondary lymphoid tissue. 14, 36, 37 Thus, the role of IFN-a/b in RBC alloimmunization may differ from their role in autoimmunity, viral infections, or immunization. Given that viral infections and multiple autoimmune diseases induce IFN-a/b production and promote RBC alloimmunization, we tested the hypothesis that IFN-a/b regulates alloimmune responses to RBC antigens. Given the large number of antigenic differences between human donors and recipients, we utilized a murine transfusion model that allows examination of alloimmune responses to a single donor RBC antigen. Using this model, we assessed the role of IFN-a/b in promoting RBC alloimmunization. Further, we assessed the contribution of cell-specific IFN-a/b signaling to the RBC alloimmune response.
MATERIALS AND METHODS

Mice
C57BL/6 and congenic C57BL/6-Ly5.1 WT mice were purchased from Charles River Laboratories. muMT-, TCRa -/-, and Zbtb46-DTR mice were purchased from The Jackson Laboratories. IFNAR1 -/-and KEL RBC transgenic mice (previously published as KEL2B mice) were previously described. 22, 38 All mice had been backcrossed to the C57BL/6 background for more than eight generations. All animal protocols were approved by the Yale Institutional Animal Care and Use Committee. In accordance to the Institutional Animal Care and Use Committee protocol, experimental groups consisted of four to five mice per independent experiment. 
RBC transfusion
Generation of bone marrow chimeras
Recipient WT C57BL/6 (CD45.21) or IFNAR1 -/-(CD45.21) mice were exposed to two rounds of X-ray irradiation (6.35 Gy, 3 hr apart) using an irradiator (X-RAD 320, Precision X-ray, Inc.). Recipients were injected IV 2 to 4 hours after irradiation with a total of 3 3 10 6 bone marrow cells from WT C57BL/6-Ly5. Zbtb46-DTR chimeras to achieve efficient conventional DC (cDC) depletion.
Measurement of anti-KEL alloantibodies
Transfusion of murine KEL RBCs induces anti-KEL production in allogeneic mice that do not express the human KEL glycoprotein. 38 These anti-KEL formed after transfusion of KEL RBCs are defined as anti-KEL alloantibodies. Serum anti-KEL IgG was measured by flow cytometric crossmatch 7, 14, 21, and 28 days after transfusion as previously described. 41 Briefly, serum from transfused mice was incubated with KEL RBCs and subsequently stained for RBC-bound IgG (goat anti-mouse IgG allophycocyanin, Jackson ImmunoResearch). Undiluted serum was used to maximize the sensitivity of the assay. The adjusted mean fluorescence intensity (MFI) was calculated by subtracting the reactivity of serum with syngeneic C57BL/6 RBCs from the reactivity of serum with KEL RBCs. Figure  data illustrate the peak antibody response, 21 to 28 days after transfusion. Flow cytometry of RBCs was performed using a flow cytometer (BD FACSCalibur) and analyzed using software (FlowJo, Tree Star).
Flow cytometric analysis
Single-cell suspensions of peripheral blood white blood cells (WBCs) and splenocytes were analyzed after RBC lysis. Marrow was collected by flushing tibias with medium. For DC analysis, spleens were minced with a razor blade before cell filtration with a 70 mmol/L nylon mesh. Suspensions were stained with fluorescently conjugated antibodies specific for cell surface proteins, including CD45.2 (Clone 104), CD138 (Syndecan-1), CD19 (6D5), TCRb (H57-597), IgD (11-26c.2a), I-A/I-E (MHC II, M5/ 114.15.2), and GL7 from Biolegend; CD45.1 (A20), CD11c (N418), B220 (RA3-6B2), and IFNAR1 (MAR1-5A3) from Ebioscience; and Fas/CD95 (Jo2) from BD Biosciences. Zombie-NIR (Biolegend) was used to exclude dead cells. Cells were acquired with a flow cytometer (MACSQuant, Miltenyi) and analyzed using computer software (FlowJo).
In vitro B-cell cultures B cells were isolated from WT and IFNAR1 -/-spleens by negative selection using a magnetic cell isolation kit (StemCell Technologies). B-cell purity analyzed by flow cytometry was 90% to 95%. B cells (1 3 10 6 /mL) were cultured in complete RPMI previously described 42 containing anti-CD40 (10 mg/mL FGK4.5) with or without recombinant IFN-a (100 U/mL, HC1040, Hycult Biotech) for 72 hours. 
Statistical analysis
Statistical analysis was performed using computer software (Prism, GraphPad). Statistical significance between two groups was determined using an unpaired t-test or Mann-Whitney U-test for parametric and nonparametric data, respectively. Significance between three groups was determined using a Kruskal-Wallis test with a Dunn's posttest. All anti-KEL IgG, germinal center (GC) B cell, and primary plasma cell data were analyzed using nonparametric tests. B cell culture data was analyzed with an unpaired two-tailed t-test. Bars on graphs indicate the mean of the data, and the circles represent individual data points from one mouse or one culture. Significance was determined for all individually performed experiments containing at least four mice per group. With the exception of B cell culture data, figures in the primary text display results of one experiment of two to three completed experiments with three to five mice per group. Results of repeated experiments are shown in Figs. S1-S4 (available as supporting information in the online version of this paper).
RESULTS
IFN-a/b regulates alloimmunization to KEL-expressing RBCs
IFN-a/b is induced in inflammatory conditions associated with increased alloimmunization. Thus, we examined whether expression of the only receptor for IFN-a/b, IFNAR, was required for RBC alloimmunization. We utilized a murine model in which donor murine RBCs express the human KEL glycoprotein in a RBC specific manner (KEL RBCs). 38 As shown in Fig. 1A 
Hematopoietic cell expression of IFN-a/b receptors in transfusion recipients is required for KEL RBC alloimmunization
IFNAR1 is expressed by multiple hematopoietic and nonhematopoietic cells. Additionally, IFNAR signaling has been reported to promote humoral immune responses by activating multiple cell types. 18 To determine whether hematopoietic or nonhematopoietic IFNAR1 expression is required for alloimmunization after KEL RBC transfusion, alloimmune responses in bone marrow chimeras were examined. Recipients were irradiated and reconstituted with donor marrow 8 weeks before transfusion. As shown in Fig. 1C 
IFNAR expression in cDCs is dispensable for RBC alloimmunization
To determine which hematopoietic cell type(s) utilize(s) IFN-a/b to promote alloantibody production, responses were assessed in mixed bone marrow chimeras that lack IFNAR1 expression in specific cell types. Given that prior studies have established a role for IFN-a/b in promoting dendritic cell maturation and antigen presentation, 43, 44 we hypothesized that IFNAR signaling in cDCs may regulate alloimmunization. To generate chimeras lacking IFNAR1 expression in cDCs, we utilized Zbtb46-DTR mice, which specifically express the DTR on cDCs. 45 2B ). Zbtb46-DTR-expressing cDCs were then depleted by injecting DT before transfusion. As a result, nearly all remaining cDCs in DT-treated Zbtb46-DTR 3 IFNAR1
-/-chimeras were derived from IFNAR1 -/-marrow (Fig. 2C) .
However, after transfusion, DT-and PBS-treated chimeras produced comparable levels of anti-KEL IgG. (Fig. 3A) . TCRa -/-3 IFNAR1 -/-chimeras were only generated with CD45.21 marrow (Fig. 3B) . However, measurement of IFNAR1 expression in T cells confirmed that TCRa -/-3 IFNAR1 -/-chimeras contained only IFNAR1-deficient T cells (Fig. 3C ). After transfusion of KEL RBCs, both groups of chimeras produced comparable amounts of anti-KEL IgG (Figs. 3D and S2B ). These results indicate that IFNAR expression by T cells is not required for alloimmunization to KEL RBCs.
IFNAR expression by B cells is required for alloimmunization to KEL RBCs
Studies of viral infection and immunization have also shown that IFN-a/b can directly promote B cell activation and antibody production. 21, 47, 48 To examine whether IFNAR signaling in B cells regulates RBC alloimmunization, mixed chimeras were generated by reconstituting irradiated CD45.21 WT mice with marrow from B celldeficient muMT-(CD45.21) mice and either WT (CD45.11) or IFNAR1 -/-(CD45.21) mice. Chimeras reconstituted with only IFNAR1 -/-marrow were also generated to serve as controls. After reconstitution, nearly all CD191 B cells in muMT-3 WT chimeras were derived from CD45.11 WT marrow (Fig. 4A) . In muMT-3 IFNAR1 -/-chimeras, expression of CD45.2 on all cells excluded a similar analysis (Fig. 4B) . However, analysis of IFNAR1 expression demonstrated that all B cells in muMT-3 IFNAR1 -/-chimeras were IFNAR1-deficient (Fig. 4C ). Upon transfusion with KEL RBCs, muMT-3 WT chimeras produced alloantibodies. However, like IFNAR1 -/-control chimeras, muMT-3 IFNAR1 -/-chimeras produced significantly lower levels of anti-KEL IgG ( Fig. S4D and S2C) . Thus, IFNAR signaling in B cells regulates alloimmunization to KEL RBCs. and S3D). Differentiation of plasma cells was also assessed 14 days after the second transfusion. The 
IFN-a/b promotes GC B-cell and plasma cell differentiation
DISCUSSION
Identifying patients with an elevated risk of RBC alloimmunization would allow interventions, such as extended antigen matching, to inhibit alloimmunization and hemolytic events. However, diagnostic tests to predict alloimmunization have not been developed. This is in part due to the lack of understanding of cellular and molecular pathways that promote alloimmunization. In this study, we demonstrate that recipient expression of IFNAR is required for alloimmunization to the human KEL glycoprotein in a murine transfusion model. Although the receptor for IFN-a/b is expressed by many nonhematopoietic and hematopoietic cell types, we demonstrate that IFNAR expression by B cells critically regulates the humoral alloimmune response. We further show that IFNAR promotes GC B cell and plasma cell differentiation after transfusion. IFN-a/b has been shown to have diverse effects on humoral immune responses to varying infectious organisms and immunogenic antigens. [21] [22] [23] [24] Given that IFNAR1 -/-and WT mice were reported to produce similar antibody responses in many other models, 22 the abrogated RBC alloimmune response of IFNAR1 -/-mice was unlikely due to potentially altered lymphoid architecture or hematopoiesis in IFNAR1 -/-mice. Rather, our interpretation of these data is that binding of IFN-a/b to IFNAR activates downstream signaling that is required for alloimmunization to KEL RBCs. This conclusion is supported by the finding that treatment of WT mice with an IFNAR1-blocking antibody significantly inhibited the anti-KEL IgG response. These findings provide insight into previously reported studies in mouse transfusion models. Treatment of recipient mice with inflammatory pathogen-associated molecular patterns, including poly(I:C) and CpG, promotes alloimmunization to RBCs expressing KEL or other alloantigens. [13] [14] [15] Poly(I:C) is a mimetic of viral doublestranded RNA (dsRNA) that induces robust production of IFN-a/b by many cell types. Our demonstration that IFNAR expression is required for KEL RBC alloimmunization raises the possibility that poly(I:C) promotes alloimmunization by inducing IFN-a/b. However, this should be formally tested in transfusion models that require the use of poly(I:C) to induce alloimmunization. Multiple studies have successfully utilized mixed bone marrow chimeras to examine the role of IFNAR signaling in specific cell types. 21, 50 
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